Abstract |
In an attempt to predict the antitumor activity of a new podophyllotoxin analogue, NK 611, in the treatment of lung cancer, we compared the drug with etoposide and teniposide using four human small cell lung cancer (SCLC) cell lines, SBC-2, -3, -4, -7, and two non-small cell lung cancer cell lines, ABC-1, EBC-1. In terms of the fifty percent tumor growth inhibitory concentration (IC 50) determined by MTT assay, teniposide was most potent among the drugs. The degree of cross-resistance of each drug was investigated using an etoposide-resistant SCLC subline (SBC-3/ETP), an adriamycin-resistant subline (SBC-3/ADM 100), and a cisplatin-resistant subline (SBC-3/CDDP). As for relative resistant (the ratio of IC 50 for resistant subline to that for the parent subline), NK 611 was least cross-resistant to etoposide, adriamycin, and cisplatin among drugs tested. These results indicate that NK 611 may play a role in a salvage chemotherapy for patients with resistant SCLC.
|
Authors | N Takigawa, T Ohnoshi, H Ueoka, K Kiura, T Moritaka, M Tabata, Y Segawa, T Shibayama, K Gemba, T Matsumura |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 20
Issue 4
Pg. 473-7
(Mar 1993)
ISSN: 0385-0684 [Print] Japan |
PMID | 8383949
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Tetrazolium Salts
- Thiazoles
- NK 611
- Etoposide
- Teniposide
- thiazolyl blue
- Podophyllotoxin
|
Topics |
- Adenocarcinoma
(pathology)
- Antineoplastic Agents
(pharmacology)
- Carcinoma, Small Cell
(pathology)
- Carcinoma, Squamous Cell
(pathology)
- Cell Division
(drug effects)
- Drug Resistance
- Drug Screening Assays, Antitumor
- Etoposide
(pharmacology)
- Humans
- Lung Neoplasms
(pathology)
- Podophyllotoxin
(analogs & derivatives, pharmacology)
- Teniposide
(pharmacology)
- Tetrazolium Salts
(pharmacology)
- Thiazoles
(pharmacology)
- Tumor Cells, Cultured
|